Factor V Leiden Testing: DNA-Based Genetic Testing from Whole Blood
Factor V Leiden mutation is detected using DNA-based genetic testing (PCR-based molecular methods) performed on whole blood samples collected in standard EDTA (purple-top) tubes, not through traditional coagulation assays 1.
Test Methodology
The gold standard for Factor V Leiden detection is direct DNA genotyping that identifies the specific G→A transition at position 1691 in exon 10 of the factor V gene (also designated as factor V c.*97G>A in current nomenclature). Modern laboratories use:
- Quantitative real-time PCR (qPCR) with allele-specific discrimination technology 2
- Automated microparticle enzyme immunoassay platforms (e.g., Abbott LCx) 3
- Hemi-nested allele-specific PCR directly from whole blood 4
These molecular methods have high analytical sensitivity and specificity and are the current standard 1.
Sample Collection
- Specimen type: Whole blood
- Collection tube: Standard EDTA (purple-top) anticoagulant tube
- Volume: Typically 3-5 mL, though some assays can work with as little as 5 microliters 4
- No special preparation required: Patient does not need to be fasting or off anticoagulation
Critical Advantage Over Functional Assays
While older functional tests (APC resistance assays using modified APTT or Russell Viper Venom Time) exist 5, 6, 7, DNA-based testing is superior because it:
- Works regardless of anticoagulation status (warfarin, heparin, DOACs do not interfere) 7
- Not affected by acute thrombosis or inflammatory states
- Definitively identifies homozygotes vs heterozygotes 3, which is critical since homozygotes have high-risk thrombophilia requiring different management 1
- Not influenced by lupus anticoagulants or other coagulation abnormalities 8
When to Order Testing
Based on the 2025 ACMG guidelines 1, testing is recommended for:
Strong indications:
- VTE at unusual sites (cerebral, splanchnic veins)
- VTE provoked by pregnancy/postpartum or oral contraceptives
- VTE with family history of thrombophilia in first/second-degree relatives
- VTE with first-degree relative affected at young age
- Low APC resistance on functional testing
Suggested indications:
- Recurrent VTE
- Siblings of known homozygotes
- Asymptomatic pregnant women with first-degree relative who is a homozygote or compound heterozygote
- Pregnant women with prior VTE considering thromboprophylaxis decisions
Common Pitfalls to Avoid
- Do NOT order routine screening in unselected VTE patients or general population 1
- Do NOT test for arterial thrombosis (MI, stroke) as there is insufficient evidence of association 1
- Do NOT order MTHFR testing alongside Factor V Leiden—MTHFR is explicitly not recommended for thrombophilia evaluation 1
- Avoid functional APC resistance assays alone as they can give false results with anticoagulants, lupus anticoagulants, or in certain transplant scenarios 8
The DNA test definitively identifies the mutation, guides duration of anticoagulation, informs family planning decisions, and identifies high-risk homozygotes who require more aggressive thromboprophylaxis strategies.